Inari Medical (NARI)
(Real Time Quote from BATS)
$55.31 USD
+0.41 (0.75%)
Updated Jul 22, 2024 02:46 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
NARI 55.31 +0.41(0.75%)
Will NARI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NARI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NARI
Intuitive Surgical (ISRG) Hits All-Time High: Will It Go Higher?
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
NARI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain Inari Medical (NARI) for Now
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
Inari's (NARI) Expanding Product Portfolio Offsets Competition
Other News for NARI
Med-tech and healthcare stocks with upside during 2Q earnings - Baird
Insider Sale: Chief Medical Officer Thomas Tu Sells Shares of Inari Medical Inc (NARI)
Director William Hoffman Sells 60,000 Shares of Inari Medical Inc (NARI)
Inari Medical just downgraded at Needham, here's why
Needham cuts Inari to hold, cites competitive concerns